What question did this study set out to answer?

To identify biomarkers predictive of response to dual EGFR and PI3K inhibition in breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS4-05-05: EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

View Full Paper

Ask AI

Bookmark

Authors

DWD. J. WiisniewskiCenter for Cancer Research DVD. J. VoellerCenter for Cancer Research YAY. A. AddissieCenter for Cancer Research

Discussion

Member takes

Implication

Combination therapy using EGFR and PI3K inhibitors shows promise in breast cancers with specific genetic profiles, highlighting potential treatment strategies.

Key Points

To identify biomarkers predictive of response to dual EGFR and PI3K inhibition in breast cancer.
Studied the frequency of EGFR amplification and PI3K mutations using cBioPortal and Caris datasets.
Utilized triple negative breast cancer cell lines BT20, MDA-MB-468, and MDA-MB-231 for in vitro experiments.
Measured signaling pathways through immunoblot analyses and assessed drug synergy via cell viability and apoptosis assays.
Conducted xenograft studies for in vivo tumor growth evaluations.
EGFR amplification is present in 1-2.5% of breast cancer patients, more common in TNBC and specific subtypes.
Patients with EGFR amplification demonstrated worse overall survival compared to non-amplified counterparts.
54-71% of EGFR amplified tumors show mutations in the PI3K pathway.
Combination therapy showed significant reduction in signaling and increased apoptosis in specific cell lines compared to control.
Only the combination therapy led to a significant reduction in tumor volume in xenograft models.

Cite This Study

Wiisniewski et al. (2026) studied this question.

synapsesocial.com/papers/6996a887ecb39a600b3ef50d https://doi.org/10.1158/1557-3265.sabcs25-ps4-05-05

View Full Paper

Ask AI

Bookmark

Implication

Combination therapy using EGFR and PI3K inhibitors shows promise in breast cancers with specific genetic profiles, highlighting potential treatment strategies.

Abstract PS4-05-05: EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS4-05-05: EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider